The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer
and the third leading cause of cancer mortality worldwide. The development of effective …

Background No adjuvant treatment has been established for patients who remain at high
risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We …

Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

The liver is the sixth most common site of primary cancer in humans, and generally arises in
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the
fourth most common malignancy and the second leading cause of tumor-related death …

Cell therapy practices date back to the 19th century and continue to expand on
investigational and investment grounds. Cell therapy includes stem cell-and non–stem cell …

In light of a global rise in obesity and type 2 diabetes, non-alcoholic fatty liver disease
(NAFLD) and non-alcoholic steatohepatitis (NASH) represent an increasingly important …